Potassium Canrenoate

DRUG2 trials

Sponsors

Policlinico San Donato S.p.A., Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Conditions

COVID-19 Acute Respiratory Distress SyndromeHeart Failure

Phase 2

Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19

Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoCOVID-19 Acute Respiratory Distress Syndrome

Start: 2022-09-30End: 2023-12-31Target: 180Updated: 2022-05-20

Phase 4

Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)

Not yet recruitingCTIS2025-520660-18-00

Policlinico San Donato S.p.A.Heart Failure

Target: 368Updated: 2025-11-17